Search Results - "Kappos, Ludwig"

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis by Gold, Ralf, Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Giovannoni, Gavin, Selmaj, Krzysztof, Tornatore, Carlo, Sweetser, Marianne T, Yang, Minhua, Sheikh, Sarah I, Dawson, Katherine T

“…In this randomized trial involving patients with multiple sclerosis, BG-12 (dimethyl fumarate) reduced clinical relapses, disability progression, and MRI…”
Get full text

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis by Siller, Nelly, Kuhle, Jens, Muthuraman, Muthuraman, Barro, Christian, Uphaus, Timo, Groppa, Sergiu, Kappos, Ludwig, Zipp, Frauke, Bittner, Stefan

“…Background: Monitoring neuronal injury remains one key challenge in early relapsing-remitting multiple sclerosis (RRMS) patients. Upon axonal damage,…”
Get full text

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials by Kappos, Ludwig, Wolinsky, Jerry S, Giovannoni, Gavin, Arnold, Douglas L, Wang, Qing, Bernasconi, Corrado, Model, Fabian, Koendgen, Harold, Manfrini, Marianna, Belachew, Shibeshih, Hauser, Stephen L

“…Accumulation of disability in multiple sclerosis may occur as relapse-associated worsening (RAW) or steady progression independent of relapse activity (PIRA),…”
Get more information

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response by Kuhle, Jens, Kropshofer, Harald, Haering, Dieter A, Kundu, Uma, Meinert, Rolf, Barro, Christian, Dahlke, Frank, Tomic, Davorka, Leppert, David, Kappos, Ludwig

“…OBJECTIVETo assess the value of blood neurofilament light chain (NfL) as a biomarker of recent, ongoing, and future disease activity and tissue damage and its…”
Get full text

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice by Sastre-Garriga, Jaume, Pareto, Deborah, Battaglini, Marco, Rocca, Maria A., Ciccarelli, Olga, Enzinger, Christian, Wuerfel, Jens, Sormani, Maria P., Barkhof, Frederik, Yousry, Tarek A., De Stefano, Nicola, Tintoré, Mar, Filippi, Massimo, Gasperini, Claudio, Kappos, Ludwig, Río, Jordi, Frederiksen, Jette, Palace, Jackie, Vrenken, Hugo, Montalban, Xavier, Rovira, Àlex

“…Early evaluation of treatment response and prediction of disease evolution are key issues in the management of people with multiple sclerosis (MS). In the past…”
Get full text

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis by Barro, Christian, Benkert, Pascal, Disanto, Giulio, Tsagkas, Charidimos, Amann, Michael, Naegelin, Yvonne, Leppert, David, Gobbi, Claudio, Granziera, Cristina, Yaldizli, Özgür, Michalak, Zuzanna, Wuerfel, Jens, Kappos, Ludwig, Parmar, Katrin, Kuhle, Jens

“…See Giovannoni (doi:10.1093/brain/awy200) for a scientific commentary on this article. Biomarkers of tissue damage in multiple sclerosis are urgently needed…”
Get full text

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions by Elliott, Colm, Wolinsky, Jerry S, Hauser, Stephen L, Kappos, Ludwig, Barkhof, Frederik, Bernasconi, Corrado, Wei, Wei, Belachew, Shibeshih, Arnold, Douglas L

“…Background: Chronic lesion activity driven by smoldering inflammation is a pathological hallmark of progressive forms of multiple sclerosis (MS). Objective: To…”
Get full text

No consensus about consensus? by Kappos, Ludwig

Get full text

Ofatumumab versus Teriflunomide in Multiple Sclerosis by Hauser, Stephen L, Bar-Or, Amit, Cohen, Jeffrey A, Comi, Giancarlo, Correale, Jorge, Coyle, Patricia K, Cross, Anne H, de Seze, Jerome, Leppert, David, Montalban, Xavier, Selmaj, Krzysztof, Wiendl, Heinz, Kerloeguen, Cecile, Willi, Roman, Li, Bingbing, Kakarieka, Algirdas, Tomic, Davorka, Goodyear, Alexandra, Pingili, Ratnakar, Häring, Dieter A, Ramanathan, Krishnan, Merschhemke, Martin, Kappos, Ludwig

“…In two identical trials involving a total of 1882 patients with multiple sclerosis, the human anti-CD20 monoclonal antibody ofatumumab was associated with a…”
Get full text

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria by Thompson, Alan J, Banwell, Brenda L, Barkhof, Frederik, Carroll, William M, Coetzee, Timothy, Comi, Giancarlo, Correale, Jorge, Fazekas, Franz, Filippi, Massimo, Freedman, Mark S, Fujihara, Kazuo, Galetta, Steven L, Hartung, Hans Peter, Kappos, Ludwig, Lublin, Fred D, Marrie, Ruth Ann, Miller, Aaron E, Miller, David H, Montalban, Xavier, Mowry, Ellen M, Sorensen, Per Soelberg, Tintoré, Mar, Traboulsee, Anthony L, Trojano, Maria, Uitdehaag, Bernard M J, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian G, Reingold, Stephen C, Cohen, Jeffrey A

“…The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research and clinical practice. Scientific advances in the past 7 years…”
Get full text

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis by Disanto, Giulio, Barro, Christian, Benkert, Pascal, Naegelin, Yvonne, Schädelin, Sabine, Giardiello, Antonella, Zecca, Chiara, Blennow, Kaj, Zetterberg, Henrik, Leppert, David, Kappos, Ludwig, Gobbi, Claudio, Kuhle, Jens, Kuhle, Jens, Lorscheider, Johannes, Yaldizli, Özgür, Derfuss, Tobias, Kappos, Ludwig, Disanto, Giulio, Zecca, Chiara, Gobbi, Claudio, Benkert, Pascal, Achtnichts, Lutz, Nedeltchev, Krassen, Kamm, Christian P, Salmen, Anke, Chan, Andrew, Lalive, Patrice H, Pot, Caroline, Schluep, Myriam, Granziera, Cristina, Du Pasquier, Renaud, Müller, Stefanie, Vehoff, Jochen

“…Objective Neurofilament light chains (NfL) are unique to neuronal cells, are shed to the cerebrospinal fluid (CSF), and are detectable at low concentrations in…”
Get full text

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis by Elliott, Colm, Belachew, Shibeshih, Wolinsky, Jerry S, Hauser, Stephen L, Kappos, Ludwig, Barkhof, Frederik, Bernasconi, Corrado, Fecker, Julian, Model, Fabian, Wei, Wei, Arnold, Douglas L

“…Chronic active and slowly expanding lesions with smouldering inflammation are neuropathological correlates of progressive multiple sclerosis pathology. T1…”
Get full text

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis by Montalban, Xavier, Hauser, Stephen L, Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Comi, Giancarlo, de Seze, Jérôme, Giovannoni, Gavin, Hartung, Hans-Peter, Hemmer, Bernhard, Lublin, Fred, Rammohan, Kottil W, Selmaj, Krzysztof, Traboulsee, Anthony, Sauter, Annette, Masterman, Donna, Fontoura, Paulo, Belachew, Shibeshih, Garren, Hideki, Mairon, Nicole, Chin, Peter, Wolinsky, Jerry S

“…Patients with primary progressive MS who received the anti-CD20+ humanized antibody ocrelizumab were less likely to have clinical deterioration that was…”
Get full text

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis by Hauser, Stephen L, Bar-Or, Amit, Comi, Giancarlo, Giovannoni, Gavin, Hartung, Hans-Peter, Hemmer, Bernhard, Lublin, Fred, Montalban, Xavier, Rammohan, Kottil W, Selmaj, Krzysztof, Traboulsee, Anthony, Wolinsky, Jerry S, Arnold, Douglas L, Klingelschmitt, Gaelle, Masterman, Donna, Fontoura, Paulo, Belachew, Shibeshih, Chin, Peter, Mairon, Nicole, Garren, Hideki, Kappos, Ludwig

“…In two trials involving patients with relapsing multiple sclerosis, the anti-CD20+ monoclonal antibody ocrelizumab was associated with lower annualized relapse…”
Get full text

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis by Montalban, Xavier, Gold, Ralf, Thompson, Alan J, Otero-Romero, Susana, Amato, Maria Pia, Chandraratna, Dhia, Clanet, Michel, Comi, Giancarlo, Derfuss, Tobias, Fazekas, Franz, Hartung, Hans Peter, Havrdova, Eva, Hemmer, Bernhard, Kappos, Ludwig, Liblau, Roland, Lubetzki, Catherine, Marcus, Elena, Miller, David H, Olsson, Tomas, Pilling, Steve, Selmaj, Krysztof, Siva, Aksel, Sorensen, Per Soelberg, Sormani, Maria Pia, Thalheim, Christoph, Wiendl, Heinz, Zipp, Frauke

“…Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling…”
Get full text

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study by Kappos, Ludwig, Butzkueven, Helmut, Wiendl, Heinz, Spelman, Timothy, Pellegrini, Fabio, Chen, Yi, Dong, Qunming, Koendgen, Harold, Belachew, Shibeshih, Trojano, Maria

“…Background: Confirmed Expanded Disability Status Scale (EDSS) progression occurring after a fixed-study entry baseline is a common measure of disability…”
Get full text

Otto van Eikema Hommes – 7 February 1932 – 16 August 2022 by Kappos, Ludwig, Barkhof, Frederik, Uitdehaag, Bernard

Get full text

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results by Gold, Ralf, Arnold, Douglas L, Bar-Or, Amit, Fox, Robert J, Kappos, Ludwig, Mokliatchouk, Oksana, Jiang, Xiaotong, Lyons, Jennifer, Kapadia, Shivani, Miller, Catherine

“…Background: Dimethyl fumarate (DMF) demonstrated favorable benefit–risk in relapsing-remitting multiple sclerosis (RRMS) patients in phase-III DEFINE and…”
Get full text

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis by Kappos, Ludwig, Wiendl, Heinz, Selmaj, Krzysztof, Arnold, Douglas L, Havrdova, Eva, Boyko, Alexey, Kaufman, Michael, Rose, John, Greenberg, Steven, Sweetser, Marianne, Riester, Katherine, O’Neill, Gilmore, Elkins, Jacob

“…In this trial, daclizumab high-yield process (a monoclonal antibody that binds to CD25 and modulates interleukin-2 signaling) was more effective than…”
Get full text

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis by O'Connor, Paul, Wolinsky, Jerry S, Confavreux, Christian, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Benzerdjeb, Hadj, Truffinet, Philippe, Wang, Lin, Miller, Aaron, Freedman, Mark S

“…In this trial, teriflunomide reduced annualized relapse rates and disability progression over 108 weeks of treatment in patients with relapsing MS, although…”
Get full text